We are live on ! Find out more
TVRD

Tvardi Therapeutics
TVRD

160 hedge funds and large institutions have $354M invested in Tvardi Therapeutics in 2022 Q4 according to their latest regulatory filings, with 16 funds opening new positions, 56 increasing their positions, 42 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

105% more call options, than puts

Call options by funds: $1.51M | Put options by funds: $734K

33% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 42

9% more capital invested

Capital invested by funds: $324M → $354M (+$30M)

0.03% less ownership

Funds ownership: 1.79% → 1.76% (-0.03%)

3% less funds holding

Funds holding: 165 → 160 (-5)

20% less first-time investments, than exits

New positions opened: 16 | Existing positions closed: 20

Holders
160
Holders Change
-5
Holders Change %
-3.03%
% of All Funds
2.57%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
16
Increased
56
Reduced
42
Closed
20
Calls
$1.51M
Puts
$734K
Net Calls
+$772K
Net Calls Change
-$107K

Top Buyers

Rank Fund Capital Flow
1
Bank of America
Bank of America
North Carolina
+$6.44M
2
ECM
ExodusPoint Capital Management
New York
+$2.54M
3
BlackRock
BlackRock
New York
+$1.59M
4
Assenagon Asset Management
Assenagon Asset Management
Luxembourg
+$727K
5
Ameriprise
Ameriprise
Minnesota
+$696K

Top Sellers

Rank Fund Capital Flow
1
FCM
Farallon Capital Management
California
-$4.49M
2
JP Morgan Chase
JP Morgan Chase
New York
-$2.95M
3
RCMNY
Rubric Capital Management (New York)
New York
-$2.5M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$2.17M
5
AWCI
Alpine Woods Capital Investors
New York
-$1.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
AF
126
Allworth Financial
California
$8.04K +$380 +1 +5%
Carson Wealth (CWM LLC)
127
Carson Wealth (CWM LLC)
Nebraska
$8K -$13.3K -35 -61%
ME
128
McIlrath & Eck
Washington
$7.91K – – –
SWA
129
Sutton Wealth Advisors
Florida
$7.91K – – –
Nisa Investment Advisors
130
Nisa Investment Advisors
Missouri
$7K – – –
CG
131
Cutler Group
California
$6K – – –
CUAMC
132
China Universal Asset Management Company
China
$5.86K +$380 +1 +7%
BFEC
133
Benjamin F. Edwards & Company
Missouri
$5K – – –
S
134
SignatureFD
Georgia
$3.72K -$2.28K -6 -38%
SIC
135
SJS Investment Consulting
Ohio
$3.22K – – –
AWM
136
Accurate Wealth Management
Florida
$3.04K +$3.04K +8 New
LJHT
137
Laurie J. Hall Trustee
$3K -$1.52K -4 -36%
US Bancorp
138
US Bancorp
Minnesota
$2.81K – – –
FCA
139
FinTrust Capital Advisors
South Carolina
$2.79K – – –
HI
140
Harbour Investments
Wisconsin
$2.69K – – –
TC
141
Truvestments Capital
Florida
$2.57K – – –
CFD
142
Creative Financial Designs
Indiana
$2.36K – – –
CA
143
Clearstead Advisors
Ohio
$2.15K – – –
PTC
144
Private Trust Company
Ohio
$2K -$380 -1 -14%
Daiwa Securities Group
145
Daiwa Securities Group
Japan
$2K – – –
HCM
146
Horrell Capital Management
Arkansas
$2K – – –
MCC
147
Money Concepts Capital
Florida
$1.66K +$1.52K +4 New
LC
148
Lindbrook Capital
California
$1.47K +$1.52K +4 New
CFGS
149
Concourse Financial Group Securities
Alabama
$1.07K – – –
SIS
150
Sound Income Strategies
Florida
$1.07K – – –
4 5
6
7 8

TVRD Hedge Fund Activity: Q4 2022 in Review

160 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Tvardi Therapeutics (TVRD) for Q4 2022, worth a combined $354M — up 9.3% from $324M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of TVRD and 16 opened new positions — a net loss of 4 holders — while 42 trimmed existing stakes and 56 added.

The largest buyer was Bank of America, adding an estimated $6.44M. The largest seller was Farallon Capital Management, cutting an estimated $4.49M.

  • 160 institutional investors held Tvardi Therapeutics (TVRD) as of Q4 2022, down from 165 in Q3 2022.
  • Funds reported $354M of Tvardi Therapeutics stock for Q4 2022, up 9.3% quarter-over-quarter.
  • 16 funds opened new Tvardi Therapeutics positions in Q4 2022 and 20 closed out, a net change of -4 holders.
  • The largest Tvardi Therapeutics buyer in Q4 2022 was Bank of America, an estimated $6.44M added.
  • The largest Tvardi Therapeutics seller in Q4 2022 was Farallon Capital Management, an estimated $4.49M sold.

Based on aggregated 13F filings for Q4 2022.